| 前收市價 | 0.4300 |
| 開市 | 0.4700 |
| 買盤 | 0.0500 |
| 賣出價 | 1.8500 |
| 拍板 | 60.00 |
| 到期日 | 2024-08-16 |
| 今日波幅 | 0.4700 - 0.4700 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 131 |
ZacksUltragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study
Ultragenyx (RARE) reports meeting primary and secondary endpoints in the late-stage study of its investigational gene therapy, DTX401, to treat glycogen storage disease type Ia.
BenzingaUltragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks' Cells
The estate of Henrietta Lacks can proceed with a lawsuit against Ultragenyx Pharmaceutical (NASDAQ:RARE) over the use of cells taken from Lacks’ body in the 1950s, as ruled by a Maryland federal court on Monday. U.S. District Judge Deborah Boardman rejected Ultragenyx’s motion to dismiss the case, determining that the estate had plausibly claimed that Ultragenyx wrongly profited from its research using the “immortal” HeLa cell line. The HeLa cells, extracted from Lacks’ cervix without her knowle
Insider MonkeyUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2024 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2024 Earnings Call Transcript May 2, 2024 Ultragenyx Pharmaceutical Inc. misses on earnings expectations. Reported EPS is $-2.02505 EPS, expectations were $-1.72. RARE isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome […]
